title: Spasticity: current and future management. Royal College of Physicians, November 13, 1997.
abstract: Tizanidine hydrochloride (Zanaflex), an alpha 2-adrenoreceptor agonist, is the first new antispasticity agent to become available in the UK for more than 20 years. It provides effective reduction of spasticity without affecting muscle strength. The mechanisms of spasticity, its measurement and management, together with the place of tizanidine in its treatment, were discussed at a symposium held at the Royal College of Physicians on November 13 1997.
mesh_terms: D002986:Clinical Trials as Topic; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005684:Gait; D006801:Humans; D009128:Muscle Spasticity / Q000188:drug therapy*; D013119:Spinal Cord Injuries / Q000188:drug therapy
chemical_list: C023754:tizanidine; D003000:Clonidine